Join
Live feed
·
PRReleasevia Quantisnow
Acrivon Therapeutics Inc. logo

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors

ByQuantisnow·Wall Street's wire, on your screen.
ACRV· Acrivon Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ACRV (Acrivon Therapeutics Inc.) and more on Quantisnow.